Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: REDX
Market: AIM
52-week High/Low: 67.80p / 23.00p
Sector: Pharma & Biotech
Market Cap: 40.69M
Phone: +44 (0)151 706 4747
Address: Royal Liverpool Univeristy Hospital, Daulby Street, Liverpool L69 3GA.
Website: RedxPharma.com
Redx Pharma Plc

Redx Pharma Plc

Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Redx Pharma Plc

RedxPharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Redx Pharma Plc


Redx Pharma Plc Snapshot

Redx Pharma (formed in September 2010) has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

Redx Anti-Infectives 

Redx Anti-Infectives Ltd is a wholly-owned subsidiary of Redx Pharma, a UK-based company discovering and developing new therapeutics for the global pharmaceutical market.

Redx has successfully applied its proprietary Redox Switch™ approach in the area of infectious disease generating a pipeline of novel antibacterial and antiviral drugs.

The recent calls from the World Health Organisation and the UK's Chief Medical Officer for greater efforts to be invested in the discovery of new antibiotics have highlighted the chronic lack of new therapies in this area. Redx Anti-Infectives, in collaboration with its partners, is playing its part in tackling this issue with a key focus on developing drugs to combat antibiotic resistance.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Redx Oncology

Redx Oncology was the first subsidiary formed by parent company Redx Pharma in April 2012. With over 190 people Redx Pharma is now one of the largest R&D pharmaceutical biotech employers in the UK and over 80 of these staff work within Redx Oncology. The company currently has a broad portfolio of novel oncology programs including three nominated development candidates (Btk, SMO, porcupine).

Redx Oncology works on small molecule approaches to cancer medicines with a focus on targeted medicines which will address key areas of unmet need such as pancreatic cancer, as well as developing second generation medicines which will treat emerging resistance to current therapies. The company also has a portfolio of immune-oncology programs which look to harness the immune system to fight the cancer. This is an area of cancer research which is showing great promise and is expected to become a key aspect of cancer therapy approaches in the future. The early results with launched antibodies such as the anti-PD-1 (Keytruda, Opdivo) and anti-CTLA-4 (Yervoy) have created a stir in the cancer research field but much remains to be done in terms of improving response rates so that this approach can benefit a wider patient population. Redx Oncology is working to develop small molecule drugs for use in combination with these antibodies to enhance their efficacy and increase the number of people who respond to treatment.

Redx Immunology

Redx Pharma announced the launch of its third subsidiary, Redx Immunology, in May 2015. The company will focus on developing new therapies for disorders of the immune system.

It is intended that Redx Immunology will deliver up to eight new drug development candidates over the near to medium term for subsequent progression into clinical trials. The launch of Redx Immunology is in line with the Group's stated strategy to develop a third therapeutic area to generate additional pipeline assets for further partnering and licencing deals. Its creation also complements Redx's current cancer-related drug programs which encompass immuno-oncology.

Redx Immunology's approach to drug discovery and development will be consistent with the Company's existing approach in its cancer and anti-infectives subsidiaries. It will focus on commercially relevant targets and seek to improve the characteristics of existing drug classes to create highly differentiated best-in-class new drugs. As with its other subsidiaries, Redx will seek partnership and licence deals at an early stage in drug development programs.

Dr Frank Armstrong (Non-Executive Chairman) joined the Company on 1 September 2014. Frank has previously led Medical Science and Innovation (MSI) in R&D at Merck Serono, Worldwide Development at Bayer and the Worldwide Medical Organisation at Zeneca. He has also been the CEO of a number of life sciences companies and has extensive experience of medical and product development in large and small company environments, leading successful product approvals in the US and EU across a range of therapeutic areas. Frank has been the CEO of five biotechnology companies (public and private) and was CEO of Fulcrum Pharma, before it was sold to private equity. In 2007, he led the sale of 454 Life Sciences for CuraGen to Roche for a consideration of $154 million. Frank has experience acting as chairman and non-executive director in the UK and USA with both private companies and a NASDAQ listed company as well as being chairman of a charitable institution. Frank has been non-executive chairman of AIM listed Summit plc (LSE: SUMM) since June 2013.

Dr Neil Murray (CEO) co-founded the Company in 2010 and has over 25 years’ experience in the pharmaceutical industry with experience of drug development, business growth and general management. He has held a variety of senior operational, commercial and R&D positions including as Global Director for Sales and Marketing with Solutia's Pharmaceutical Services business. Prior to joining Solutia he was Director of Chemical Development at Vernalis (formerly Vanguard Medica) with additional responsibility for management of the company's research portfolio. He was also European Business Development Director for SigmaAldrich before which he was External Projects Director at GlaxoWellcome with responsibility for the company's external development science. He has extensive experience of drug discovery and development and commercialisation in large and small companies across a wide range of therapeutic areas.

Mr Philip Tottey (CFO) joined the Company in 2013 and is a qualified member of the Association of Chartered Certified Accountants. Philip started his career at Grant Thornton before moving to work at the retail division of Littlewoods plc. He moved to the international media organisation, Emap plc in 1994, as Operations Director for Radio City, one of its subsidiary companies in Liverpool. In addition to this position, Philip also held a group role as finance manager for all of Emap’s North West Radio Stations, including Key 103 in Manchester and Rock FM in Preston. In his last role prior to joining the Redx Group, Phil was Deputy Chief Executive for the social enterprise business FRC Group.

 

Dr Peter Jackson (Non-Executive Director) is a co-founder of the Company and previously served as Executive Chairman before becoming a Non-Executive Director in September 2014. In 2007, Peter founded the Company’s predecessor company Bradford Pharma. From 2005 until 2010, Peter was founder and CEO of Reaxa, exploiting chemical catalyst technology for the production of drugs with lower levels of impurities to meet stricter quality standards. He is founder and non-executive director of two other biopharma ventures, ADC Biotechnology focused on production of new antibody-based cancer therapeutics, and 32 Yorkshire Process Technology, focused on development of new chemical processes for pharmaceuticals and agrochemicals. Peter has over 25 years’ experience in the sector, holding senior executive roles as commercial director then head of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI.

Mr Norman Molyneux (Non-Executive Director) was previously the CFO of the Company before becoming a Non-Executive Director in September 2014. Norman is a qualified Chartered Management Accountant and has 15 years’ experience in arranging early stage business angel and venture capital funding. Following training in accountancy with GKN, he joined PriceWaterhouseCoopers, working on many consultancy assignments with both SME and multinational companies. Following this, he returned to industry with director roles in the paper manufacturing and food manufacturing sectors in the UK. In 2000, Norman founded Acceleris Limited, an FCA regulated fund management and corporate finance firm specialising in EIS-led investment transactions. Norman holds numerous directorships fulfilling both executive and non-executive positions.

Mr Peter McPartland (Non-Executive Director) has been Non-Executive Director of the Company since October 2010. Peter has been the managing director of Reacta Biotech Ltd, a Manchester based startup, since February 2014. A graduate pharmacologist, he worked for six years as an investment analyst before joining Schroder Ventures (now Permira) in 1988. In 1994 Peter became a co-founder and general partner of SV Life Sciences (SVLS). From 1998 he began to develop his own personal interests while maintaining a part-time role at SVLS, leaving that firm in 2007 to become an independent venture capital consultant. During his spell at SV/SVLS he was a director of a number of leading companies in the field, including Shire Pharmaceuticals, Chiroscience and Triangle Pharmaceuticals.

Dr Bernhard Kirschbaum (Non-Executive Director) joined the Board in January 2016. Bernhard has over 25 years' experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company's R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently a board member of BioMedX, Protagen Diagnostics, and OMEICOS Therapeutics.

David Lawrence (Non-Executive Director) joined the Board in May 2016. David has over 25 years' experience in the biotech and pharmaceutical industries with a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs. He is currently a Non-Executive Director at Synpromics Ltd, a synthetic biology company that he co-founded. In 2014-2015 he was CEO of Sentintext Therapeutics, a biotech focussed on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices. David has been Chairman of Ambicare Health Limited, CEO of Tayside Flow Technologies Ltd and formerly worked at Chiron Vaccines (now part of Novartis), Acambis plc (now part of Sanofi), and GlaxoSmithKline.

Management

Dr Neil Murray (CEO), as above

Mr Philip Tottey (CFO), as above

Dr Derek Lindsay (COO), a co-founder of the business, is the Chief Operating Officer having joined the Company full-time in 2012. Derek was previously Director of Innovation of pharmaceutical industry consortium Britest Ltd, from 2006 to 2012. Prior to that he was R&D director of Avecia Pharmaceutical Products and had held a series of management roles in a career spanning 21 years; working in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985.

Dr Richard Armer (CSO) joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard’s expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.

Nominated Adviser & Broker
Cantor Fitzgerald Europe
One Churchill Place
London E14 5RB

Corporate Finance Adviser
Acceleris Capital Ltd
Lowry House
17 Marble Street
Manchester M2 3AW

Auditor
RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF
Legal Adviser
DWF LLP
1 Scott Place
2 Hardman Street
Manchester M3 3AA

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA

Financial PR Adviser
KTZ Communications Limited
No. 1 Cornhill
London EC3V 3ND

Redx Pharma Plc Timeline

Columns Including REDX

VIEW ALL

Market Reports Including REDX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use